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Abstract
Introduction: In this study, we sought to determine the association between red blood cell (RBC) transfusion and
outcomes in patients with acute lung injury (ALI), sepsis and shock.
Methods: We performed a secondary analysis of new-onset ALI patients enrolled in the Acute Respiratory Distress
Syndrome Network Fluid and Catheter Treatment Trial (2000 to 2005) who had a documented ALI risk factor of
sepsis or pneumonia and met shock criteria (mean arterial pressure (MAP) < 60 mmHg or vasopressor use) within
24 hours of randomization. Using multivariable logistic regression, we examined the association between RBC
transfusion and 28-day mortality after adjustment for age, sex, race, randomization arm and Acute Physiology and
Chronic Health Evaluation III score. Secondary end points included 90-day mortality and ventilator-free days (VFDs).
Finally, we examined these end points among the subset of subjects meeting prespecified transfusion criteria
defined by five simultaneous indicators: hemoglobin < 10.2 g/dL, central or mixed venous oxygen saturation <
70%, central venous pressure ≥ 8 mmHg, MAP ≥ 65 mmHg, and vasopressor use.
Results: We identified 285 subjects with ALI, sepsis, shock and transfusion data. Of these, 85 also met the above
prespecified transfusion criteria. Fifty-three (19%) of the two hundred eighty-five subjects with shock and twenty
(24%) of the subset meeting the transfusion criteria received RBC transfusion within twenty-four hours of
randomization. We found no independent association between RBC transfusion and 28-day mortality (odds ratio =
1.49, 95% CI (95% confidence interval) = 0.77 to 2.90; P = 0.23) or VFDs (mean difference = -0.35, 95% CI = -4.03 to
3.32; P = 0.85). Likewise, 90-day mortality and VFDs did not differ by transfusion status. Among the subset of
patients meeting the transfusion criteria, we found no independent association between transfusion and mortality
or VFDs.
Conclusions: In patients with new-onset ALI, sepsis and shock, we found no independent association between
RBC transfusion and mortality or VFDs. The physiological criteria did not identify patients more likely to be
transfused or to benefit from transfusion.
Keywords: erythrocyte transfusion, respiratory distress syndrome, adult therapy, sepsis therapy, treatment outcome,
intensive care unit, respiration, artificial
Introduction
Red blood cell (RBC) transfusion is common in the ICU,
with nearly half of all critically ill patients receiving at
least one transfusion during their ICU stay [1]. However,
it is not clear that RBC transfusion improves patient
outcomes. The use of RBC transfusion varies widely
among physicians, with high rates of potentially unne-
cessary transfusions [1]. Several lines of evidence indi-
cate that routine RBC transfusion in critically ill patients
is associated with excess harm, including the develop-
ment of nosocomial infection [2,3], acute lung injury
(ALI) [4,5] and death [3,6-8].
Despite evidence linking RBC transfusion to adverse
clinical outcomes and recommendations for lower trans-
fusion thresholds, certain critically ill patients may bene-
fit from RBC transfusion. RBC transfusions might
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benefit patients with sepsis by improving oxygen deliv-
ery while patients are in a state of high metabolic
demand and overall oxygen deficit. A randomized, con-
trolled trial supported this notion by demonstrating that
an early goal-directed resuscitation protocol, including
fluids, inotropes and RBC transfusion (at a hematocrit
threshold of < 30%) saved lives when administered
within 6 hours after severe sepsis diagnosis in the emer-
gency department setting [9]. These results are in con-
trast to earlier studies of hemodynamically driven
strategies aimed at supranormal oxygen delivery in the
ICU, which failed to improve outcomes [10,11].
Conflicting evidence regarding RBC transfusion and
outcomes has led to significant controversy over the use
of RBC transfusion in goal-directed sepsis resuscitation
strategies and in critically ill septic patients in the ICU
[12,13]. A 2007 survey found that only 0.1% of respond-
ing physicians complied with all 2004 Surviving Sepsis
Campaign guidelines advocating use of a goal-directed
sepsis bundle that included RBC transfusion along with
other therapeutics within the first 6 hours of resuscita-
tion [14]. In this survey, protocol-driven RBC transfu-
sion varied from 15% to 70% [14]. Current practice
guidelines [12,13] do not address the use of RBC trans-
fusion beyond the first 6 hours after sepsis diagnosis,
despite evidence that in 43% of patients, the objectives
of goal-directed therapy may not be initiated or com-
pleted within this time interval [15]. Furthermore, the
effect of RBC transfusion on clinical outcomes in ICU
patients with septic shock complicated by coexistent
ALI is unknown. The Fluid and Catheter Treatment
Trial (FACTT) trial showed that liberal volume adminis-
tration (which could include RBC transfusion) was asso-
ciated with poor outcomes in hemodynamically stable
ALI patients [16], but the primary analysis did not
examine the specific association between transfusion
and clinical outcomes. In this study, we examined
whether RBC transfusion administered in the ICU to
patients with a recent diagnosis of ALI, sepsis and shock
is independently associated with death and/or the num-
ber of days free from mechanical ventilation. We also
investigated whether a prespecified set of physiological
criteria might help identify a subset of patients most
likely to receive or benefit from transfusion.
Materials and methods
We performed a secondary analysis of the Acute
Respiratory Distress Syndrome Network (ARDSNet)
FACTT, a multicenter, randomized, controlled trial
comparing the effectiveness of two fluid management
and invasive monitoring strategies [16,17] performed
between 2000 and 2005. FACTT enrolled 1,000 subjects
within 48 hours of a new ALI diagnosis (mean time 24
hours at a median of 48 hours after hospital admission).
All subjects were randomized to a liberal or conservative
fluid management strategy and a pulmonary artery
catheter or central venous catheter for 7 days or until
they achieved unassisted ventilation. During periods of
shock (defined as mean arterial pressure (MAP) < 60
mmHg or vasopressor use), fluid management was not
dictated by the study protocol and left to the discretion
of the clinician. Transfusion was not a part of the
FACTT protocol and was initiated according to the phy-
sician’s discretion. During the primary FACTT study,
written informed consent was obtained from partici-
pants or legally authorized surrogates. All required data
elements for our secondary analysis were available in
their entirety from the FACTT database, acquired with
permission from ARDSNet and the National Heart,
Lung, and Blood Institute (NHLBI). The Institutional
Review Board of the University of Washington approved
this secondary data analysis and waived the need for
additional consent.
Eligibility and definitions
We first identified subjects with sepsis and shock within
the FACTT database. We defined “sepsis” as the presence
of a documented ALI risk factor for sepsis or pneumonia
(Figure 1). We excluded subjects with a documented ALI
risk factor for trauma or multiple transfusions, as well as
those missing transfusion data during the first 24 hours
after randomization. We defined “sepsis and shock” (here-
inafter referred to as “shock”) as a mean arterial pressure
(MAP) < 60 mmHg or vasopressor use within the first 24
hours after randomization. Finally, we identified a sub-
group of subjects with shock meeting four physiological
criteria that might identify those subjects most likely to
benefit from RBC transfusion (Figure 1). These criteria,
derived from a sepsis resuscitation trial [9], included (1)
adequate volume and pressor support, defined as central
venous pressure (CVP) ≥ 8 mmHg, MAP ≥ 65 mmHg and
use of a vasopressor; (2) poor perfusion, defined as central
venous oxygen saturation (cVO2) or mixed venous oxygen
saturation (mVO2) < 70%; and (3) anemia, defined as
hemoglobin (Hb) < 10.2 g/dL.
Data collection
Trained research coordinators collected demographic
and clinical data prospectively during the FACTT study.
These data included center, randomization arm, age,
sex, race, location, APACHE III score 24 hours prior to
randomization, baseline comorbidities, ratio of oxygen
pressure to fraction of inspired oxygen (PaO2/FiO2
ratio), Hb and ventilatory parameters, including static
pressure and tidal volume. In addition, detailed hemody-
namic information was abstracted, including vasopressor
use, MAP, cVO2, mVO2 and volume of fluid and blood
products.
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Exposure
Transfusion data recorded at 8:00 AM daily through
study day 8 were the number of packed RBC units
transfused during the preceding 24 hours. Our goal was
to examine the association between RBC transfusion
and outcomes in subjects with a new ALI diagnosis who
also met the criteria for sepsis and shock. We therefore
restricted our transfusion exposure window to the first
1000 ALI patients enrolled in 
FACTT
809 with ALI and sepsis
481 with ALI and sepsis
285 with ALI, sepsis and shock 
within 24 hours of 
randomization
85 with ALI, sepsis and shock 
meeting transfusion criteria
(Hb < 10.2 g/dL, central or mixed 
venous oxygen saturation < 70%, 
CVP ≥ 8 mm Hg, MAP ≥ 65 mm Hg, 
and vasopressor use)
191 Excluded:
No infection
328 Excluded:
Trauma (18)
Multiple transfusion (6)
Missing transfusion data (304)
196 Excluded:
No shock
158 Excluded:
Do not meet transfusion criteria
42 Excluded:
Missing data for transfusion 
criteria (Hb, cVO2 or mvO2)
Figure 1 Derivation of analysis cohorts. ALI, acute lung injury; FACTT, Fluid and Catheter Treatment Trial; Hb, hemoglobin; cVO2, central
venous oxygen saturation; mVO2, mixed venous oxygen saturation; CVP, central venous pressure; MAP, mean arterial pressure.
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24 hours after study randomization (a maximum of 72
hours after ALI diagnosis).
Outcomes
The primary outcome was the proportion of patients
who died before hospital discharge and within 28 days
after study enrollment (28-day mortality). Patients were
monitored during follow-up for 90 days or until death
or discharge to home with unassisted breathing. Second-
ary outcomes were 90-day mortality and number of ven-
tilator-free days (VFDs) by days 28 and 90 as previously
defined [18].
Statistical analysis
We performed bivariate comparisons between subjects
who did or did not receive RBC transfusions using t-
tests with unequal variance or Wilcoxon rank-sum tests
for continuous variables and c2 tests for categorical vari-
ables. To assess the independent association between
RBC transfusion and mortality at 28 and 90 days, we
performed multivariable logistic regression, adjusting for
factors which we considered potentially related to both
outcomes and the likelihood of transfusion, including
subject age [1,19,20], sex [19,20], race [19,21], APACHE
III score and FACTT randomization arm [16]. To exam-
ine the association between RBC transfusion and VFDs,
we performed multivariable negative binomial regression
adjusted for the same predetermined confounders by
using graphical analysis of predicted to observed prob-
abilities and likelihood ratio testing to demonstrate
goodness of fit. We then performed marginal means
estimation to determine the adjusted difference in mean
VFDs by transfusion status to assess goodness of fit
using a log-likelihood ratio test [22].
Because of the prevalence of missing data for transfu-
sion, we performed multiple imputation by chained
equations to account for missing data [23-25]. Addi-
tional details regarding our imputation methods are
given in Additional files 1 and 2. We repeated our pri-
mary analysis in the imputed cohort using Rubin’s rules
to generate combined risk estimates across the imputed
datasets [26]. All statistical analyses were performed
using Stata 11.0 software (State Corp., College Station,
TX, USA).
Results
Derivation of the analysis cohorts
Of the 1,000 subjects enrolled in FACTT, 809 (81%) had
ALI and a documented risk factor of sepsis and/or
pneumonia. We excluded 328 subjects (33%) with an
ALI risk factor of trauma (18 subjects), multiple transfu-
sion (6 subjects) or missing transfusion data (304 sub-
jects). We identified 285 subjects who met our criteria
for shock within the first 24 hours after randomization
(Figure 1). Of these 285 subjects, 85 (30%) met all trans-
fusion indicators outlined above.
Baseline characteristics
Fifty-three (19%) of the two hundred eighty-five subjects
with shock were transfused within twenty-four hours of
randomization, which occurred at a median of 1 day
(interquartile range (IQR) 1 to 2 days) after ICU admis-
sion and a median of 2 days (IQR 1 to 5 days) after hos-
pital admission. Transfused and nontransfused subjects
were similar in terms of age, sex, ICU location, comor-
bidities, PaO2/FiO2 ratio and randomization arm (Table
1). In bivariate comparisons, transfusion was associated
with black race (28% vs. 17%; P = 0.03), higher
APACHE III score (mean 118 vs. 103; P < 0.01), more
fluid administration in the first 24 hours (mean 6.8 vs.
5.5 L; P = 0.01) and lower baseline Hb (mean 8.5 vs. 9.7
g/dL; P < 0.01).
Outcomes
Twenty-three transfused subjects (43%) died by day 28
compared with 70 nontransfused subjects (30%) (P =
0.06). By day 28, median VFDs were zero (IQR 0 to 19)
in transfused subjects and 9 (IQR 0 to 19) in nontrans-
fused subjects (P = 0.35). In multivariable regression
analysis, we observed no independent association
between transfusion and 28-day mortality (adjusted odds
ratio (OR) = 1.49, 95% CI = 0.77 to 2.90; P = 0.23) or
VFDs (adjusted mean difference = -0.35, 95% CI = -4.03
to 3.32, P = 0.85) (Table 2). Likewise, we observed no
independent association between transfusion and 90-day
mortality (adjusted OR = 1.55, 95% CI = 0.81 to 2.96; P
= 0.19) or VFDs (adjusted difference = -10.1, 95% CI =
-23.6 to 3.42; P = 0.14) (Table 2). These results were
not appreciably changed after performing multiple
imputation of missing data (Additional file 2).
Subset analysis among subjects meeting transfusion
criteria
In the subset of subjects meeting our prespecified trans-
fusion criteria, only 20 (24%) received RBC transfusions
during the exposure period of interest. Bivariate analyses
of subject characteristics by transfusion status are
shown in Table 3. Within this subgroup, transfusion
was associated with older age (mean age = 65 vs. 51
years; P < 0.01) male sex (65% vs. 38%; P = 0.04),
greater APACHE III scores (median = 122 vs. 103; P =
0.02) and lower Hb (mean = 8.2 vs. 9.0 g/dL; P = 0.02).
Death by day 28 occurred in 10 (50%) of the transfused
subjects compared to 19 (29%) of the nontransfused
subjects (P = 0.09). By day 28, median VFDs were zero
(IQR 0 to 12.5) in transfused subjects and nine (IQR 0
to 19) in nontransfused subjects (P = 0.26). In multivari-
able regression analysis, after adjusting for our
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predetermined confounders, we observed no indepen-
dent association between transfusion and 28-day mor-
tality (adjusted OR = 2.23, 95% CI = 0.63 to 7.81; P =
0.21) or VFDs (adjusted difference = -1.34, 95% CI =
-7.50 to 4.82; P = 0.67) (Table 4). Likewise, we
observed no independent association between RBC
transfusion and 90-day mortality (adjusted OR = 2.16,
95% CI, 0.66 to 7.01; P = 0.20) or VFDs (adjusted dif-
ference = -18.4, 95% CI = -43.6 to 6.76; P = 0.15)
(Table 4). These results were not appreciably changed
after performing multiple imputation of missing data
(Additional file 2).
Discussion
The purpose of our study was to determine whether
RBC transfusion administered in the ICU is associated
with outcomes among patients with a recent diagnosis
of ALI, sepsis and shock. We found that RBC transfu-
sion in this period occurred in approximately one in five
patients. The proportion of patients receiving RBC
transfusions was similar in the subgroup of patients
Table 1 Subject characteristics in shock
Characteristics Transfused (n = 53) Not transfused (n = 232) P value
Age, years 53 (17) 52 (16) 0.52
Males 30 (57) 123 (53) 0.22
Race
White 35 (66) 149 (64) 0.03
Black 15 (28) 40 (17)
Other 3 (6) 43 (19)
Chronic comorbidities
Diabetes 11 (21) 40 (18) 0.59
Hepatic failure 2 (4) 1 (0.4) 0.03
Alcohol use 2 (4) 26 (12) 0.13
Prior myocardial infarction 0 (0) 11 (5) 0.12
Congestive heart failure 0 (0) 8 (4) 0.18
Admission type
Medical ICU 47 (89) 211 (91) 0.87
Surgical ICU 5 (9) 18 (8)
Other 1 (2) 3 (1)
Randomization
Liberal fluid (vs. conservative) 25 (47) 114 (49) 0.80
Pulmonary artery (vs. central venous) catheter 28 (53) 125 (54) 0.89
APACHE III score 118 (27) 103 (2) < 0.01
Days from ALI diagnosis to randomization 0 (0, 1) 0 (0, 1) 0.99
Days from hospital admission to randomization 2 (1, 7) 2 (1, 4) 0.18
Days from ICU admission to randomization 1 (1, 2) 1 (1, 2) 0.89
PaO2/FiO2 ratio at randomization 107 (63 to 150) 108 (73 to 154) 0.47
Physiological parameters during exposure window
Hemoglobin nadir, g/dL 8.5 (1.4) 9.7 (1.4) < 0.01
cVO2/mVO2 ratio nadir 67 (12) 67 (13) 0.76
MAP nadir, mmHg 62 (8) 63 (9) 0.47
Mean MAP, mmHg 71 (8) 73 (9) 0.19
Total fluid received, L 6.8 (4.4) 5.5 (3.2) 0.01
Multiple pressors 27 (51) 120 (52) 0.92
APACHE III, Acute Physiology and Chronic Health Evaluation III; ALI, acute lung injury; cVO2, central venous oxygen saturation (%); mVO2, mixed venous oxygen
saturation (%); MAP, mean arterial pressure (mmHg). Estimates are reported as n (%), means (SD) or medians (IQR) as appropriate.
Table 2 Outcomes with red blood cell transfusion among
subjects with shock
Parameter Adjusted estimatea (95%
CI)
P
value
Odds ratio for death
At 28 days 1.49 (0.77 to 2.90) 0.23
At 90 days 1.55 (0.81 to 2.96) 0.19
Difference in mean ventilator-free
days
Days 1 to 28 -0.35 (-4.03 to 3.32) 0.85
Days 1 to 90 -10.1 (-23.6 to 3.42) 0.14
aAdjusted for age, gender, race, Acute Physiology and Chronic Health
Evaluation III score and randomization arm. 95% CI, 95% confidence interval.
Data in center column are odds ratio or marginal means estimates (95% CI).
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meeting our specified transfusion criteria. After adjust-
ing for predetermined confounders, we found no signifi-
cant, independent association between RBC transfusion
and mortality or VFDs. The 95% CIs surrounding our
risk estimates argue that the lack of statistical signifi-
cance should be interpreted cautiously, as our risk esti-
mates included clinically relevant differences in the
direction of both benefit and harm.
Our study failed to show benefit or harm when RBC
transfusion was administered to patients with a new
diagnosis of ALI, sepsis and shock. There are several
potential explanations for this result. First, RBC transfu-
sion in this study was administered to patients in the
ICU up to 72 hours after they met the criteria for sepsis
and ALI. The clinical setting and/or timing of RBC
transfusion may in fact be important in determining its
benefit or harm [5,9,27,28]. A single randomized trial
Table 3 Subject characteristics in shock meeting physiological criteria for transfusion
Characteristics Transfused (n = 20) Not transfused (n = 65) P value
Age, years 65 (15) 51 (14) < 0.01
Male 13 (65) 25 (38) 0.04
Race
White 14 (70) 45 (69) 0.49
Black 5 (25) 11 (17)
Other 1 (5) 9 (14)
Chronic comorbidities
Diabetes 5 (26) 14 (22) 0.71
Hepatic failure 1 (5) 0 (0) 0.07
Alcohol use 0 (0) 9 (14) 0.09
Prior myocardial infarction 0 (0) 3 (5) 0.39
Congestive heart failure 0 (0) 5 (8) 0.26
Admission type
Medical 16 (80) 61 (94) 0.08
Surgical 4 (20) 4 (6)
Other 0 (0) 0 (0)
Randomization arm
Liberal fluid (vs. conservative) 11 (55) 29 (45) 0.42
Pulmonary artery (vs. central venous) catheter 14 (70) 46 (71) 0.95
APACHE III score 122 (7) 103 (3) 0.02
Days from ALI diagnosis to randomization 1 (0 to 1) 1 (0 to 1) 0.96
Days from hospital admission to randomization 2 (1 to 11) 2 (1 to 4) 0.49
Days from ICU admission to randomization 1 (0.5 to 1.5) 1 (1 to 2) 0.20
PaO2/FiO2 ratio at randomization 107 (60 to 144) 89 (66 to 152) 0.85
Physiological parameters during exposure window
Hemoglobin nadir, g/dL 8.2 (1.2) 9.0 (0.8) 0.02
cVO2/mVO2 ratio nadir 59 (1) 59 (10) 0.99
MAP nadir 62 (7) 62 (9) 0.80
Mean MAP 72 (8) 73 (7) 0.70
Multiple pressors 12 (60) 32 (49) 0.45
Total fluid received, L 5.4 (3.0) 5.0 (2.9) 0.54
APACHE III, Acute Physiology and Chronic Health Evaluation III; ALI, acute lung injury; PaO2/FiO2, ratio of arterial oxygen pressure to fraction of inspired oxygen;
cVO2, central venous oxygen saturation (%); mVO2, mixed venous oxygen saturation (%); MAP, mean arterial pressure (mmHg). Estimates are reported as n (%),
means (SD) or medians (IQR) as appropriate.
Table 4 Outcomes with red blood cell transfusion among
subjects with shock meeting physiological criteria for
transfusiona
Parameter Adjusted estimate (95%
CI)b
P
value
Odds ratio for death
At 28 days 2.23 (0.63 to 7.81) 0.21
At 90 days 2.16 (0.66 to 7.01) 0.20
Difference in mean ventilator-free
days
Days 1 to 28 -1.34 (-7.50 to 4.82) 0.67
Days 1 to 90 -18.4 (-43.6 to 6.76) 0.15
aTransfusion criteria were defined by five simultaneous indicators: hemoglobin
< 10.2 g/dL, central or mixed venous oxygen saturation < 70%, central venous
pressure ≥ 8 mmHg, MAP ≥ 65 mmHg and vasopressor use. bAdjusted for
age, gender, race, Acute Physiology and Chronic Health Evaluation III score
and randomization arm. Data in center column are odds ratio or marginal
means estimates (95% CI).
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published by Rivers et al. [9] showed a mortality benefit
when RBC transfusion was administered to patients
with severe sepsis in the emergency department as part
of a larger goal-directed resuscitation strategy that
included fluid and vasopressor support. This resuscita-
tion protocol was administered to enrolled subjects in
an emergency department setting within 6 hours after a
sepsis diagnosis. Thereafter, subjects were admitted to
an ICU and underwent care as determined by their phy-
sicians. Notably, 64% of subjects in the treatment arm of
the Rivers et al. trial were exposed to RBC transfusion
within the first 6 hours of therapy. In contrast, observa-
tional studies in the ICU have not consistently demon-
strated that RBC transfusion improves oxygen delivery
in fluid-replete septic subjects [28-30] and instead raises
concern regarding increased complications, including
nosocomial infection [2,3,31], ALI [3-5,8] and death
[3,6-8,32]. In an observational study of 160 ICU patients
with septic shock, delayed goal-directed resuscitation
and transfusion up to 48 hours after diagnosis were
associated with higher risk of ALI [5]. Similarly to these
observational studies, our findings may reflect a lack of
benefit when transfusion is administered beyond the
initial 6-hour resuscitation window or for reasons other
than protocol-driven resuscitation in severe sepsis.
Finally, RBC transfusion may carry minimal beneficial
effects or even harmful effects on patient outcomes
independently of other resuscitative strategies, such as
volume resuscitation or vasopressor support.
Despite our efforts to identify a subset of subjects
with shock whom transfusion might benefit, we
observed no improvement in outcomes with RBC
transfusion. Although transfusion criteria were met in
one of four subjects, we observed no treatment asso-
ciation when adjusting for these factors in subgroup
analysis. Consistent with prior work [28-30,33], our
study suggests that physiological indicators may not
necessarily identify those patients likely to benefit from
RBC transfusion. While randomized data in patients
with septic shock are lacking, there is growing experi-
mental evidence that transfusion of stored RBCs can
potentially harm patients with preexisting inflamma-
tion or impaired microvascular perfusion. According to
the current “two-hit” hypothesis of transfusion injury
[34], RBC units may contain bioactive particles capable
of influencing the cellular injury that leads to organ
failure in susceptible patients with preexisting insults
such as sepsis or mechanical ventilation [4,34,35]. In
addition, in vivo models have demonstrated that older
RBC units exhibit reduced deformability [36,37], which
may actually impair capillary flow and oxygen delivery
in an already compromised microvascular system
[38,39]. It is therefore possible that RBC transfusion
administered beyond the first 6 hours of illness may
paradoxically be harmful in the very patients that we
hope will benefit.
Our study has several limitations. First, transfusion
data for a significant number of subjects were missing.
Because complete case analysis in the setting of missing
data may be limited by both reduced power and residual
bias [23,26], we performed a sensitivity analysis using
multiple imputation of missing values, which provided
results similar to our primary analysis. The combination
of missing RBC transfusion data and the small propor-
tion of patients who met our “shock” definition limited
our study’s power to detect statistically significant asso-
ciations between transfusion and outcomes (minimum
detectable difference in mortality = 19% based on an
overall mortality rate of 30% and two-sided a = 0.05).
While pooled blood products such as fresh frozen
plasma (FFP) may also have an effect on patient out-
comes, missing data and low FFP transfusion rates in
our cohort precluded our ability to include FFP as a
meaningful covariate. Furthermore, we cannot exclude
the possibility of residual bias related to unignorable
missing data (missing not at random) or other covariates
either not present or insufficiently captured in the data-
base, including age of transfused blood [40], the indica-
tion for transfusion, concomitant therapies such as fluid
administration and the manner in which transfusion was
administered. Though we carefully defined sepsis, shock
and physiological criteria on the basis of objective mea-
sures within a fixed time period, misclassification of
shock due to etiologies other than sepsis is a potential
limitation of our study. We also could not determine
the reason why physicians chose to transfuse individuals
or whether transfusion was administered concomitantly
with other resuscitation strategies. The decision to
administer RBC transfusion may depend on a host of
factors, including patient-, hospital- and provider-level
characteristics [1,14]. Understanding factors that contri-
bute to transfusion practice variability is an important
avenue of future study, because blood products are a
limited and costly health care resource. Last, our study
cannot determine whether RBC transfusion is a mean-
ingful component of early goal-directed therapy within
the first 6 hours of severe sepsis. It is important to note
that our patients likely differed significantly, with regard
to their stage of illness, indication for transfusion and
concomitant therapy, from those enrolled in the rando-
mized trial evaluating early goal-directed therapy in the
emergency department setting [9]. Nonetheless, some
form of goal-directed resuscitation likely extends beyond
the first 6 hours of severe sepsis into the ICU period.
Previous work suggests that delayed goal-directed ther-
apy may be associated with increased complications in
critically ill septic patients [5]. Despite its limitations,
our study builds on previous work suggesting that RBC
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transfusion beyond 6 hours of presentation may not
improve mortality in critically ill patients with septic
shock and coexistent ALI and that physiological criteria
may not identify those patients likely to benefit from
transfusion in the ICU setting.
Conclusions
We did not observe a statistically significant benefit or
harm associated with RBC transfusion among patients
with a recent diagnosis of ALI, sepsis and shock. In
addition, there was no statistically significant difference
in outcomes among the subset of subjects meeting pre-
specified physiological transfusion criteria. While not
meeting statistical significance, our observed risk esti-
mates do not exclude the possibility of clinically relevant
transfusion-related benefit or harm. These data add to
our understanding of the use of RBC transfusion in
patients with a recent diagnosis of ALI undergoing
resuscitation in the ICU, suggesting that physiological
indicators may not identify those patients likely to bene-
fit from transfusion therapy. Future studies are needed
to verify these results in larger cohorts to account for
potential modifiers, including age of transfused blood
and other resuscitative strategies.
Key messages
• RBC transfusion is of unclear benefit to patients
with established ALI and severe sepsis.
• In this study, physiological criteria did not identify
patients more likely to be transfused or to benefit
from transfusion.
• Future studies are needed to examine potential
modifiers, including age of transfused blood and
other resuscitative strategies.
Additional material
Additional file 1: Methods for Missing Data Analysis. This file
presents subject characteristics among patients with shock, according to
the presence or absence of RBC transfusion data. It also details the
methods used for multiple imputation of missing data for RBC
transfusion and other covariates. Table E1 Subject characteristics in
shock by the presence or absence of transfusion data. ALI, acute
lung injury; APACHE III, Acute Physiology and Chronic Health Evaluation
III; MICU, medical ICU; SICU, surgical ICU; PaO2/FiO2, ratio of arterial
oxygen pressure to fraction of inspired oxygen; cVO2/mVO2, ratio of
central venous oxygen saturation to mixed venous oxygen saturation;
MAP, mean arterial pressure; SD, standard deviation; IQR, interquartile
range. Table E2 Imputation variables with number of missing values
in subjects with shock. ALI, acute lung injury; MICE, multiple imputation
using chained equations; FACTT, Fluid and Catheter Treatment Trial;
APACHE III, Acute Physiology and Chronic Health Evaluation III; MICU,
medical ICU; SICU, surgical ICU; PaO2/FiO2, ratio of arterial oxygen
pressure to fraction of inspired oxygen; PaO2, arterial oxygen pressure;
PaCO2, arterial carbon dioxide pressure; BUN, blood urea nitrogen; MAP,
mean arterial pressure; CVP, central venous pressure.
Additional file 2: Results of Imputation Analysis. This file presents the
results of multivariate regression analysis performed in the imputation
cohort. Table E3 Outcomes with red blood cell transfusion among
subjects with sepsis and shock within the imputation cohort. ALI,
acute lung injury; 95% CI, 95% confidence interval; APACHE III, Acute
Physiology and Chronic Health Evaluation III.
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